Navigation Links
GPhA Says BIO Cries Wolf on Senate Biogenerics Proposal
Date:7/9/2009

ARLINGTON, Va., July 9 /PRNewswire/ -- The Generic Pharmaceutical Association (GPhA) released the following statement today from GPhA President and CEO Kathleen Jaeger on The Biotechnology Industry Organization's (BIO's) erroneous claims regarding the Senate HELP Biogenerics amendments.

"BIO's erroneous claims that anything less than an unprecedented 13 years of market exclusivity will harm innovation flies in the face of the recent Federal Trade Commission (FTC) report that such long periods of exclusivity are NOT needed to spark innovation. In fact, FTC suggested that because of their extremely robust intellectual property protection in this sector, 'no' to little market exclusivity is required.

"Both the White House and the Office of Management and Budget (OMB) also specifically stated that an unprecedented 12 to 14 years of market exclusivity would NOT achieve what should be our shared goal of balancing pharmaceutical innovation and much needed consumer access.

"While the generic industry still supports the proven successful Hatch-Waxman model as contained in the bipartisan 'Promoting Innovation and Access to Lifesaving Medicines Act,' we have commended the President for working to move this issue forward by recommending a

7-year exclusivity compromise.

"Countless Americans are waiting for more affordable biogenerics to treat their serious medical conditions and it is clear that 12 to 14 years of exclusivity will do nothing to get them the help they desperately need.

"It is a shame that in an attempt to protect the profits of Amgen, Genentech and other biotech companies, BIO and its supporters are misleading Congress. It's time to put patients over profits."

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 69% of the total prescriptions dispensed in the United States, but only 16% of all dollars spent on prescription drugs. For more information about the industry, visit www.gphaonline.org.


'/>"/>
SOURCE Generic Pharmaceutical Association (GPhA)
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels
2. Retired Supreme Court Justice Sandra Day OConnor and Former House Speaker Newt Gingrich Address Senate Special Committee on Aging, Calling for Urgent Action Against Alzheimers Disease
3. National ePrescribing Patient Safety Initiative Supports Senates Call for Physicians to Adopt Electronic Prescribing, Improving Patient Safety
4. MichBio Leader Cites New Senate Biosciences Task Force and House Subcommittee as Evidence of States Growing Awareness of Industrys Economic Importance
5. TechNet Urges Swift U.S. Senate Approval of FCC Nominees Julius Genachowski and Robert McDowell
6. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
7. Biogenerics Will Save Billions, Says Hospira CEO
8. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
9. Coalition for a Competitive Pharmaceutical Market Launches New Print Ad Campaign Highlighting Need for Meaningful Biogenerics Legislation
10. CBO: Biogenerics Would Save Federal Government $6.6 Billion Over Ten Years
11. Hospira Supports Newly Introduced Biogenerics Legislation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... January 12, 2017 , ... ... INTERFUSE® IS A SUCCESS , VTI, Vertebral Technologies, Inc., announces the successful ... laterally expandable device. Since September 2016, VTI (Vertebral Technologies, Inc.) has partnered ...
(Date:1/12/2017)... , January 12, 2017 ... the world,s biggest facility for producing mycorrhizae. The Centre ... nutrient tapping potential of mycorrhizae and developed a technology ... ... http://mma.prnewswire.com/media/456932/PRNE_TERI_Logo.jpg) The TERI facility has ...
(Date:1/11/2017)... ... 11, 2017 , ... Phase 1 clinical trial data published ... investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. The 50 women ... these heavily pretreated patients saw clinical benefit from the drug, with at least ...
(Date:1/11/2017)... , ... January 11, 2017 , ... ... year and costing healthcare systems more than $23.7 billion, healthcare systems are ... , Among the most common sepsis-causing pathogens are bacteria and the yeast ...
Breaking Biology Technology:
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic ... permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se ... tumor en 2017, con múltiples sitios previstos a lo largo de ... ... el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se ...
(Date:12/16/2016)... NEW YORK , Dec. 16, 2016 The global ... reach USD 12.14 billion by 2021 from USD 5.31 billion in ... ... market is mainly driven by technological advancements in medical devices, launch ... devices, rising preference for wireless connectivity among healthcare providers, and increasing ...
(Date:12/15/2016)... ... Markets has announced the addition of the "Global Military Biometrics Market ... the global military biometrics market to grow at a CAGR of 7.5% ... based on an in-depth market analysis with inputs from industry experts. The ... years. The report also includes a discussion of the key vendors operating ...
Breaking Biology News(10 mins):